Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Oxera study into the UK Generic medicines market
A new independent report by economics consultancy Oxera has underlined the critical importance of the UK generic medicines sector and how, via free competition, it provides sustained and significant savings to the NHS creating greater patient access.
Better access. Better health
Read our guide to Generic and biosimilars medicines market and pricing
Better access. Better health.
The British Generic Manufacturers Association (BGMA) represents the interests of UK-based manufacturers and suppliers of generic and biosimilar medicines and promotes the development and understanding of the generic and biosimilars medicines industry in the United Kingdom.
We have a strong focus on quality
The British Generic Manufacturers Association (BGMA) has launched a forum in conjunction with the MHRA to focus on ensuring the manufacturing quality of generic medicines in the UK.
We reflect our members’ views at UK and European levels
We represent the views and interests of our members and industry generally to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union and the media. Find out more about joining us.

Latest news

Highlights

Twitter

18.07.2019
Read our report commissioned with @OxeraConsulting to find out how generic medicines compare to the ‘original’: https://t.co/ZrrSJSIXMP #OxeraGenericMedicines #genericmedi
16.07.2019
The Oxera report, commissioned by us, finds that on average, generic selling prices are 70-90% lower than the originator four years after entry on the market, saving the #NHS money. Read the full report on our website: https://t.co/caMYGeQVZZ #OxeraGenericMedicines #medicine
15.07.2019
For expert analysis of how the UK generics market is functioning and the challenges posed by Brexit, read the latest blog post by Warwick Smith, our Director General, or download the free-to-access Oxera report: https://t.co/caMYGeQVZZ #OxeraGenericMedicines
12.07.2019
Check out this recent independent report from @OxeraConsulting, commissioned by us, which underlines the critical importance of the UK generic medicines sector. Download the full report on our website: https://t.co/caMYGf8wRx #OxeraGenericMedicines #genericmedicine
11.07.2019
Can you guess how much the price of a medicine typically falls after it comes off patent? Watch our video explainer or download the Oxera generics market report to find out: https://t.co/caMYGeQVZZ #OxeraGenericMedicines #NHS #savings

10 things you need to know

1
Generic medicines meet the same standards of quality, safety and efficacy as originator brands.
2
Generics have to demonstrate that they are bioequivalent to the original product - i.e., they deliver equal medical benefits to the patient.
3
Generic competition saves the NHS more than £13.5bn per annum.
4
The average cost to the NHS of a generic medicine is £3.80, whilst the average cost of a branded medicine is £20.95.
5
On one product alone, based on current usage, the generics industry has saved the taxpayer £1.1bn.
6
In the UK, a free market approach with competition between manufacturers and incentives for GPs to prescribe and pharmacists to dispense generics has led to a high market share (76%) for generic products.
7
Generic prices in the UK are the lowest in the developed world and are constrained by free market competition.
8
The market share that generics reach and the savings they generate are dependent upon national legislation and regulation.
9
Further growth and NHS savings are constrained by regulatory delays and costs, and the actions of some originator companies in trying to avoid or delay generic competition.
10
Competition from generics also stimulates the research based pharmaceutical industry to develop new medicines.